Cytotoxic T lymphocyte-associated antigen-4-Ig (CTLA-4-Ig) suppresses Staphylococcus aureus-induced CD80, CD86, and pro-inflammatory cytokine expression in human B cells.
Abatacept
/ immunology
Adult
Antigen-Presenting Cells
/ drug effects
Arthritis, Rheumatoid
/ immunology
B-Lymphocytes
/ drug effects
B7-2 Antigen
/ genetics
CD28 Antigens
/ genetics
Cells, Cultured
Cytokines
/ genetics
Female
Gene Expression
/ drug effects
Humans
Immune Checkpoint Inhibitors
/ immunology
Male
Middle Aged
Staphylococcus aureus
/ immunology
T-Lymphocytes, Cytotoxic
/ drug effects
Abatacept
CD80
CD86
CTLA-4
IL-6
Rheumatoid arthritis
TNF-α
Journal
Arthritis research & therapy
ISSN: 1478-6362
Titre abrégé: Arthritis Res Ther
Pays: England
ID NLM: 101154438
Informations de publication
Date de publication:
30 03 2020
30 03 2020
Historique:
received:
27
09
2019
accepted:
24
02
2020
entrez:
2
4
2020
pubmed:
2
4
2020
medline:
12
1
2021
Statut:
epublish
Résumé
Cytotoxic T lymphocyte-associated antigen-4-Ig (CTLA-4-Ig) competes with CD28 for binding CD80/CD86 on antigen-presenting cells (APCs) to limit T cell activation. B cells are believed to be important APCs in the pathogenesis of autoimmune diseases and express CD80/CD86 after activation; however, relatively little is known about the effect of CTLA-4-Ig on B cells. This study tested the impact of CTLA-4-Ig on human B cell responses. Human blood B cells were purified from healthy donors and activated in the presence of CTLA-4-Ig or the L6-Ig control protein in vitro. RT-q-PCR and immunofluorescence staining were performed to detect activation marker expression. ELISA was conducted to measure cytokine secretion. The CD80/CD86 levels on the surface of the memory B cells in the blood of 18 patients with rheumatoid arthritis (RA) were detected using immunofluorescence staining. CTLA-4-Ig suppressed the expression of Staphylococcus aureus (SAC)-induced CD80, CD86, TNFA, and IL6 in human B cells at the transcriptional level. Furthermore, CTLA-4-Ig concomitantly decreased SAC-induced CD80/CD86 surface expression on and TNF-α and IL-6 secretion from B cells. On the other hand, T cell-dependent (TD) stimulation-induced B cell activation, proliferation, plasma cell differentiation, and antibody secretion were not affected by CTLA-4-Ig. As expected, TD stimulation-induced surface CD80 was hindered by CTLA-4-Ig. Notably, a blockade of CD80/CD86 on the surface of the memory B cells was observed in the patients with RA after abatacept (CTLA-4-Ig) treatment. In a portion of the RA patients, restoration of CD80/CD86 staining on the surface of the memory B was detected starting in the 3rd month of abatacept treatment. Interestingly, the surface levels of CD80/CD86 on the patients' memory B cells positively correlated with disease activity. We found that CTLA-4-Ig directly suppressed SAC-induced B cell activation in vitro. Obstruction of CD80 and CD86 on the surface of the memory B cells was detected in the RA patients after abatacept treatment. Blocking CD80/CD86 on B cells by CTLA-4-Ig may hinder T cell activation and associated with the disease activity of RA in vivo. Our findings indicate that CTLA-4-Ig may regulate humoral responses by modulating B cell activation and interfering T cell-B cell interaction.
Sections du résumé
BACKGROUND
Cytotoxic T lymphocyte-associated antigen-4-Ig (CTLA-4-Ig) competes with CD28 for binding CD80/CD86 on antigen-presenting cells (APCs) to limit T cell activation. B cells are believed to be important APCs in the pathogenesis of autoimmune diseases and express CD80/CD86 after activation; however, relatively little is known about the effect of CTLA-4-Ig on B cells. This study tested the impact of CTLA-4-Ig on human B cell responses.
METHODS
Human blood B cells were purified from healthy donors and activated in the presence of CTLA-4-Ig or the L6-Ig control protein in vitro. RT-q-PCR and immunofluorescence staining were performed to detect activation marker expression. ELISA was conducted to measure cytokine secretion. The CD80/CD86 levels on the surface of the memory B cells in the blood of 18 patients with rheumatoid arthritis (RA) were detected using immunofluorescence staining.
RESULTS
CTLA-4-Ig suppressed the expression of Staphylococcus aureus (SAC)-induced CD80, CD86, TNFA, and IL6 in human B cells at the transcriptional level. Furthermore, CTLA-4-Ig concomitantly decreased SAC-induced CD80/CD86 surface expression on and TNF-α and IL-6 secretion from B cells. On the other hand, T cell-dependent (TD) stimulation-induced B cell activation, proliferation, plasma cell differentiation, and antibody secretion were not affected by CTLA-4-Ig. As expected, TD stimulation-induced surface CD80 was hindered by CTLA-4-Ig. Notably, a blockade of CD80/CD86 on the surface of the memory B cells was observed in the patients with RA after abatacept (CTLA-4-Ig) treatment. In a portion of the RA patients, restoration of CD80/CD86 staining on the surface of the memory B was detected starting in the 3rd month of abatacept treatment. Interestingly, the surface levels of CD80/CD86 on the patients' memory B cells positively correlated with disease activity.
CONCLUSIONS
We found that CTLA-4-Ig directly suppressed SAC-induced B cell activation in vitro. Obstruction of CD80 and CD86 on the surface of the memory B cells was detected in the RA patients after abatacept treatment. Blocking CD80/CD86 on B cells by CTLA-4-Ig may hinder T cell activation and associated with the disease activity of RA in vivo. Our findings indicate that CTLA-4-Ig may regulate humoral responses by modulating B cell activation and interfering T cell-B cell interaction.
Identifiants
pubmed: 32228715
doi: 10.1186/s13075-020-2138-x
pii: 10.1186/s13075-020-2138-x
pmc: PMC7106629
doi:
Substances chimiques
B7-2 Antigen
0
CD28 Antigens
0
Cytokines
0
Immune Checkpoint Inhibitors
0
Abatacept
7D0YB67S97
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
64Subventions
Organisme : Bristol-Myers Squibb
ID : IM101-571
Pays : International
Organisme : Ministry of Science and Technology
ID : MOST 106-2320-B-010-015
Pays : International
Références
Ann Rheum Dis. 2016 Apr;75(4):709-14
pubmed: 26359449
Immunity. 1995 Nov;3(5):541-7
pubmed: 7584144
J Immunol. 1999 Jul 15;163(2):659-67
pubmed: 10395655
J Immunol. 2005 Dec 15;175(12):7867-79
pubmed: 16339522
RMD Open. 2018 Mar 30;4(1):e000564
pubmed: 29657830
Science. 1992 Aug 7;257(5071):792-5
pubmed: 1496399
Science. 1995 Nov 10;270(5238):985-8
pubmed: 7481803
J Autoimmun. 2019 Jul;101:145-152
pubmed: 31054942
J Immunol. 2001 Oct 15;167(8):4710-8
pubmed: 11591802
Ann Rheum Dis. 2003 Nov;62 Suppl 2:ii55-9
pubmed: 14532151
Arthritis Rheum. 2008 Apr;58(4):953-63
pubmed: 18383390
J Cell Physiol. 2005 Dec;205(3):437-43
pubmed: 15895390
Nat Rev Immunol. 2011 Nov 25;11(12):852-63
pubmed: 22116087
J Immunol. 2000 Jul 15;165(2):680-90
pubmed: 10878340
Ann Rheum Dis. 2008 Apr;67(4):547-54
pubmed: 17921185
Nat Immunol. 2002 Nov;3(11):1097-101
pubmed: 12368911
J Immunol. 2009 Jan 15;182(2):890-901
pubmed: 19124732
Curr Opin Immunol. 2008 Dec;20(6):639-45
pubmed: 18775493
Immunity. 1997 Dec;7(6):885-95
pubmed: 9430233
Eur J Immunol. 2014 Apr;44(4):1143-55
pubmed: 24338929
Science. 1993 Jul 30;261(5121):609-12
pubmed: 7688139
J Immunol. 2007 Aug 1;179(3):1516-23
pubmed: 17641017
J Immunol. 2007 Oct 15;179(8):5109-16
pubmed: 17911596
Nat Rev Immunol. 2010 Apr;10(4):236-47
pubmed: 20224569
J Immunol. 2009 Dec 1;183(11):7054-62
pubmed: 19915057
Arthritis Res Ther. 2009;11(6):R176
pubmed: 19930661
J Biol Chem. 2002 Mar 8;277(10):7766-75
pubmed: 11726649
J Immunol. 2009 Dec 15;183(12):7661-71
pubmed: 19933871
J Immunol. 2007 Mar 1;178(5):2803-12
pubmed: 17312124
Ann Rheum Dis. 2009 Jul;68(7):1220-7
pubmed: 18772191
Arthritis Rheum. 1996 Jan;39(1):34-40
pubmed: 8546736
N Engl J Med. 2005 Sep 15;353(11):1114-23
pubmed: 16162882
Ann Rheum Dis. 2012 Nov;71(11):1815-9
pubmed: 22615458
Arthritis Res Ther. 2007;9(2):R38
pubmed: 17425783
J Immunol. 1999 Dec 15;163(12):6386-92
pubmed: 10586028
Curr Opin Rheumatol. 2010 May;22(3):307-15
pubmed: 20090526
Int Arch Allergy Immunol. 2011;155(3):205-11
pubmed: 21293141
Cell Immunol. 1995 Apr 1;161(2):226-35
pubmed: 7535196
J Biol Chem. 1997 Jun 20;272(25):15613-9
pubmed: 9188449
J Exp Med. 1991 Sep 1;174(3):561-9
pubmed: 1714933
Arthritis Rheum. 1995 Jan;38(1):44-8
pubmed: 7818570
Ann Intern Med. 2006 Jun 20;144(12):865-76
pubmed: 16785475
Trends Immunol. 2005 Apr;26(4):180-5
pubmed: 15797507
Ann Rheum Dis. 2010 Sep;69(9):1580-8
pubmed: 20699241